Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.

BACKGROUND LDL particles differ in size and density. Individuals with LDL profiles that peak in relatively small, dense particles have been reported to be at increased risk of coronary artery disease. We hypothesized that response to coronary disease therapy in such individuals might differ from response in individuals whose profiles peak in larger, more buoyant LDL. We examined this hypothesis in the Stanford Coronary Risk Intervention Project, an angiographic trial that compared multifactorial risk-reduction intervention with the usual care of physicians. METHODS AND RESULTS For 213 men, a bimodal frequency distribution of peak LDL density (g/mL) determined by analytical ultracentrifugation was used to classify baseline LDL profiles as "buoyant mode" (density < or = 1.0378) or "dense mode" (density > 1.0378). Coronary disease progression after 4 years was assessed by rates of change (mm/y, negative when arteries narrow) of minimum artery diameter. Rates for buoyant-mode subjects were -0.038 +/- 0.007 (mean +/- SEM) in usual care (n = 65) and -0.039 +/- 0.010 in intervention (n = 56; P = .6). Rates for dense-mode subjects were -0.054 +/- 0.012 in usual care (n = 51) and -0.008 +/- 0.009 in intervention (n = 41, P = .007). Lipid changes did not account for this difference in angiographic response. CONCLUSIONS Different types of LDL profile may predict different-responses to specific therapies, perhaps because metabolic processes determine both LDL profiles and responses to therapies.

[1]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[2]  P. Tijssen,et al.  Practice and theory of enzyme immunoassays , 1985 .

[3]  C. Packard,et al.  Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[4]  R. Krauss,et al.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.

[5]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[6]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[7]  R. Krauss,et al.  Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. , 1992, Journal of lipid research.

[8]  P. Wilson,et al.  Effect of Gender, Age, and Lipid Status on Low Density Lipoprotein Su bf raction Distribution: Results from the Framingham Offspring Study , 1987, Arteriosclerosis.

[9]  C. Packard,et al.  Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. , 1994, Atherosclerosis.

[10]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[11]  V. Schumaker,et al.  Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. , 1994, Advances in protein chemistry.

[12]  A. Slyper,et al.  Low-density lipoprotein density and atherosclerosis. Unraveling the connection. , 1994, JAMA.

[13]  R. Krauss Heterogeneity of plasma low‐density lipoproteins and atherosclerosis risk , 1994, Current opinion in lipidology.

[14]  D H Blankenhorn,et al.  Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. , 1990, Circulation.

[15]  V. Fuster,et al.  Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.

[16]  W. Santamore,et al.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.

[17]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[18]  K. Gould,et al.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.

[19]  S. Azen,et al.  Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.

[20]  R. Krauss,et al.  Detection and quantitation of LDL subfractions , 1992 .

[21]  E L Bolson,et al.  Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. , 1986, Circulation.

[22]  Effects of the lipid intervention in the Stanford Coronary Risk Intervention Project , 1996 .

[23]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[24]  B. G. Brown,et al.  Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. , 1994, Journal of the American College of Cardiology.

[25]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[26]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[27]  G. Nelson Blood Constituents. (Book Reviews: Blood Lipids and Lipoproteins. Quantitation, Composition, and Metabolism) , 1972 .